StonvexLoading…
StonvexStonvexStonvexCore line items from ASTH's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-08-05 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $1.00B | $965.10M | $3.18B | $2.23B | $1.28B |
Operating Income | Not available | $28.53M | $78.53M | $60.13M | $40.92M |
Net Income | Not available | $14.44M | $22.49M | $16.49M | $16.11M |
EPS (Diluted) | $0.32 | $0.29 | $0.46 | $0.33 | $0.33 |
Total Assets | Not available | $2.36B | $2.22B | $2.24B | $1.44B |
Total Liabilities | Not available | $1.78B | $1.66B | $1.68B | $904.40M |
Cash & Equivalents | Not available | $478.38M | $429.47M | $462.23M | $339.70M |
Free Cash Flow OCF − CapEx | Not available | $64.06M | $104.49M | $110.44M | $103.04M |
Shares Outstanding | Not available | 49.05M | 48.89M | 49.31M | 49.16M |